Hepatic Failure/GI/Endocrine Emergencies
Transfusion
Current guidelines recommend a transfusion threshold of 7 g/dL for hospitalized hemodynamically
stable patients, including those in the ICU, and a threshold of 8 g/dL in patients with preexisting
cardiovascular disease. This recommendation does not extend to patients with acute coronary
syndrome.
A higher hemoglobin threshold may be appropriate in patients with hypotension or who are
bleeding rapidly.
Platelet transfusion, typically if the platelet count is less than 50,000/mm3, should be considered.
Endoscopy
Diagnostic endoscopy
Used to diagnose and assess the risk posed by the bleeding lesion(s). Therapeutic endoscopy
may also be used for the lesion(s) to reduce the risk of bleeding recurrence (discussed later in
the chapter).
ii.
Patients with UGIB should generally have a diagnostic endoscopy within 24 hours.
iii.
Patients who are hemodynamically unstable and those with a suspected variceal UGIB should
have a diagnostic endoscopy as soon as possible and no later than 12 hours after presentation.
iv.
Erythromycin or metoclopramide may be used when a large amount of blood in the stomach
would hinder an endoscopy; however, routine use is not recommended. Use reduces the need
for repeated endoscopy (OR 0.55; 95% CI, 0.32β0.94) but does not alter the need for blood
products, length of hospital stay, or need for surgery.
Endotracheal intubation before endoscopy may be indicated to prevent aspiration, but patient
selection is controversial.
vi.
Endoscopic findings predict the risk of rebleeding and guide further therapies.
| (a) | Nonvariceal UGIB: Stigmata of recent hemorrhage from a peptic ulcer predict the risk of |
|---|
further bleeding and guide management decisions (Table 6).
Risk of
Rebleeding
Stigmata of
Recent Hemorrhage
Forrest
Grade
Prevalence
Rebleeding Rate
High
Active spurting bleeding
IA
9.3% (spurting and oozing)
55% (spurting and oozing)
Active oozing bleeding
IB
Nonbleeding visible vessel
IIA
6.1%
43%
Adherent clot
IIB
6.5%
22%
Low
Flat pigmented spot
IIC
13.1%
10%
Clean base
III
52.6%
5%
Information from: Laine L, Peterson W. Bleeding peptic ulcer. N Engl J Med 1994;331:717-27; Enestvedt BK, Gralnek IM, Mattek N, et al. An evaluation of endoscopic
indication and findings related to nonvariceal upper-GI hemorrhage in a large multicenter consortium. Gastrointest Endosc 2008;67:422-9; and Laine L, Jensen DM.
| (b) | Variceal UGIB: If active variceal hemorrhage is confirmed, endoscopic and pharmacologic |
|---|
therapy should be initiated.
Therapeutic endoscopy
Can be used in conjunction with a diagnostic endoscopy to treat the source of UGIB once it
has been identified
ii.
Non-variceal UGIB
| (a) | Peptic ulcer |
|---|---|
| (1) | Endoscopic therapy should be used for lesions with active spurting, active oozing, or |
a non-bleeding visible vessel.